Featured Articles

  1. FDA Continues Diversity Push 3/15/2024

    Review the FDA's revised 2016 diversity guidance, which establishes clear expectations and standardizes recommendations for gathering and reporting race and ethnicity data.

  2. Rare Disease Prioritization Model And Landscape Analysis 3/15/2024

    Uncover how a global pharmaceutical company seeking to identify promising indications among rare diseases to develop preclinical candidate molecules received an in-depth disease analysis to guide its strategic decision-making.

  3. A New Era For Patient Recruitment And Retention In Rare Disease 3/15/2024

    Pharma and biotech companies prioritize innovation in areas of high and rare unmet need. Though the R&D landscape for these rare diseases can be difficult to navigate, changes are on the horizon.

  4. Best Practices For Harmonizing Global Data Disclosure 2/20/2024

    Learn how sponsors can address the challenge of submitting clinical trial data in a consistent and compliant manner by examining internal processes to identify and close gaps.

  5. Harnessing The Power of Real-World Data In Clinical Trial Planning 2/20/2024

    As the availability of RWD grows, it creates opportunities for sponsors to use true patient insights to support their clinical strategy and bring treatments to patients in need.

  6. The Pharmaceutical Industry: 2024 (And Beyond) Predictions 1/24/2024

    DCTs, RWD, IRA … our industry predictions for 2024 are filled with acronyms. As we delve into 2024, explore what trends are hot ― and not ― for the coming year, and their impact on the industry.

  7. Diversity In Clinical Trials: How Companies Are Tackling The Issue 1/24/2024

    Experts from Genentech, Moderna, and Patientory share how collaborative approaches involving technology and multiple resources can improve health outcomes and increase diversity in clinical trials.

  8. Top 5 Insights From FDA Workshop On Enhancing Trial Diversity 1/24/2024

    Read about how this workshop served as a reminder of the need for diversity in patient recruitment and the shared commitment across the spectrum of clinical trial stakeholders.

  9. Beyond KOLs: Involving All Stakeholders In The Recruitment Process 1/19/2024

    Consider this proactive approach to patient recruitment that has the potential to ensure a more dynamic and responsive strategy, and is suited for the rapidly changing landscape of clinical trials.

  10. In Vivo Outlook 2024: A Health Care Metamorphosis 1/19/2024

    Predicting the future in the biopharma realm is inherently challenging. Read this report for insights into the evolving dynamics of the healthcare and biopharma sectors in the coming year.